Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEVERANCE: Adjuvant Everolimus in High-Risk HCC
NCT06972758Phase 2Not yet recruiting
- Sponsor
- Yonsei University
- Start
- Jul 2025
- Primary completion
- Jul 2030
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of everolimus in hepatocellular carcinoma (HCC), sponsored by Yonsei University. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
everolimus
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06972758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06972758.